Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use
OwnerDavid Lew Simoninventor
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition comprising an α3β4 nicotinic receptor antagonist effective to diminish the brain-derived feeling of pleasure due to increased dopamine in the pleasure-reward center of the brain typically associated with administration of an opioid agonist analgesic, a muscle relaxant, an anti-seizure medication, an anxiolytic drug, an amphetamine, a central nervous system stimulant, a tetrahydrocannabinol or that associated with an otherwise pleasurable or self-reinforcing behavior.
Claims24
) A pharmaceutical composition comprising a benzodiazepine and an α3β4 nicotinic receptor antagonist, and a suitable carrier thereof.
) A pharmaceutical composition comprising a barbiturate and an α3β4 nicotinic receptor antagonist, and a suitable carrier thereof.
) A pharmaceutical composition comprising an amphetamine and an α3β4 nicotinic receptor antagonist, and a suitable carrier thereof.
) A pharmaceutical composition comprising a tetrahydrocannabinol derivative and an α3β4 nicotinic receptor antagonist, and a suitable carrier thereof.
) A pharmaceutical composition comprising cocaine and an α3β4 nicotinic receptor antagonist, and a suitable carrier thereof.
) A method of treating repetitive compulsive behavior, said method comprising the administration of an α3β4 nicotinic receptor antagonist in association with said repetitive compulsive behavior.
) The method of claim 6 above where the repetitive compulsive behavior is self-mutilation.
) The method of claim 6 above where the repetitive compulsive behavior is eating.
) The method of claim 6 above where the repetitive compulsive behavior is nicotine self-administration.
) The method of claim 6 above where the repetitive compulsive behavior is kleptomania.
) The method of claim 6 above where the repetitive compulsive behavior is compulsive gambling.
) A method for treating obsessive compulsive disorder, said method comprising the administration of an α3β4 nicotinic receptor antagonist.
) A method for treating psychosis, said method comprising the administration of an α3β4 nicotinic receptor antagonist.
) A method for treating alcoholic humans, said method comprising the administration of 18-methoxycoronaridine.
) The claim of claim 1 above where the α3β4 nicotinic receptor antagonist is 18-methoxycoronaridine.
) The claim of claim 2 above where the α3β4 nicotinic receptor antagonist is 18-methoxycoronaridine.
) The claim of claim 3 above where the α3β4 nicotinic receptor antagonist is 18-methoxycoronaridine.
) The claim of claim 4 above where the α3β4 nicotinic receptor antagonist is 18-methoxycoronaridine.
) The claim of claim 5 above where the α3β4 nicotinic receptor antagonist is 18-methoxycoronaridine.
) The claim of claim 7 above where the α3β4 nicotinic receptor antagonist is 18-methoxycoronaridine.
) The claim of claim 8 above where the α3β4 nicotinic receptor antagonist is 18-methoxycoronaridine.
) The claim of claim 9 above where the α3β4 nicotinic receptor antagonist is 18-methoxycoronaridine.
) The claim of claim 10 above where the α3β4 nicotinic receptor antagonist is 18-methoxycoronaridine.
) The claim of claim 11 above where the α3β4 nicotinic receptor antagonist is 18-methoxycoronaridine.